Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Bose P, Vachhani P, Cortes JE. Treatment of relapsed/refractory acute myeloid leukemia. Curr. Treat. Options Oncol. 18(3), 17 (2017).
  MedlineGoogle Scholar
• 2. Megías-Vericat JE, Martínez-Cuadrón D, Sanz MÁ, Montesinos P. Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review. Ann. Hematol. 97(7), 1115–1153 (2018).
  Medline CASGoogle Scholar
• 3. Döhner H, Estey E, Grimwade D et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4), 424–447 (2017).
  MedlineGoogle Scholar
• 4. Thol F, Schlenk RF, Heuser M, Ganser A. How I treat refractory and early relapsed acute myeloid leukemia. Blood 126(3), 319–327 (2015).
  Medline CASGoogle Scholar
• 5. Montesinos P, Bergua J, Infante J et al. Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus. Ann. Hematol. 98(11), 2467–2483 (2019).
  MedlineGoogle Scholar
• 6. Eguchi M, Minami Y, Kuzume A, Chi S. Mechanisms underlying resistance to FLT3 inhibitors in acute myeloid leukemia. Biomedicines 8(8), 245 (2020).
  CASGoogle Scholar
• 7. Megías-Vericat JE, Ballesta-López O, Barragán E, Martínez-Cuadrón D, Montesinos P. Tyrosine kinase inhibitors for acute myeloid leukemia: a step toward disease control? Blood Rev. (2020) (Epub ahead of print).
  MedlineGoogle Scholar
• 8. Tarver TC, Hill JE, Rahmat L et al. Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations. Blood Adv. 4(3), 514–524 (2020).
  Medline CASGoogle Scholar
• 9. Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339(1), b2700 (2009).
  MedlineGoogle Scholar
• 10. Takahashi S. Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications. J. Hematol. Oncol. 4(13), 1–10 (2011).
  MedlineGoogle Scholar
• 11. Mori M, Kaneko N, Ueno Y et al. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Invest. New Drugs 35(5), 556–565 (2017). • The preclinical study demonstrates FLT3 inhibition by gilteritinib at low nanomolar concentration that supported its evaluation in clinical trials.
  Medline CASGoogle Scholar
• 12. Leischner H, Albers C, Grundler R et al. SRC is a signaling mediator in FLT3-ITD - But not in FLT3-TKD-positive AML. Blood 119(17), 4026–4033 (2012).
  Medline CASGoogle Scholar
• 13. Patnaik MM. The importance of FLT3 mutational analysis in acute myeloid leukemia. Leuk. Lymphoma 59(10), 2273–2286 (2018).
  Medline CASGoogle Scholar
• 14. Smith CC, Perl AE, Altman JK et al. Comparative assessment of FLT3 variant allele frequency by capillary electrophoresis and next-generation sequencing in FLT3mut+ patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) who received gilteritinib therapy [abstract]. Blood 130(Suppl. 1), 1411–1411 (2017).
  Google Scholar
• 15. Park IK, Mundy-Bosse B, Whitman SP et al. Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia. Leukemia 29(12), 2382–2389 (2015).
  Medline CASGoogle Scholar
• 16. James AJ, Smith CC, Litzow M et al. Pharmacokinetic profile of gilteritinib: a novel FLT-3 tyrosine kinase inhibitor. Clin. Pharmacokinet. 835 [Epub ahead of print] (2020). • Focuses on the drug–drug interaction of gilteritinib highlighting that coadministration of gilteritinib with CYP3A4 or multidrug and toxin extrusion 1 substrates did not impact substrate concentrations.
  Google Scholar
• 17. Smith CC, Levis MJ, Litzow MR et al. Pharmacokinetic profile and pharmacodynamic effects of ASP2215, a selective, potent inhibitor of FLT3/AXL, in patients with relapsed or refractory acute myeloid leukemia: results from a first-in-human phase 1/2 study [abstract]. Blood 126(23), 4836–4836 (2015).
  Google Scholar
• 18. Smith CC, Levis MJ, Litzow MR et al. Pharmacokinetics and pharmacodynamics of gilteritinib in patients with relapsed or refractory acute myeloid leukemia [abstract]. J. Clin. Oncol. 34, 7026–7026 (2016).
  Google Scholar
• 19. Astellas Pharma US Inc. “XOSPATA(R) (gilteritinib): US prescribing information.” [Online] (2018). www.accessdata.fda.gov/drugsatfda_docs/label/2019/211349s001lbl.pdf
  Google Scholar
• 20. Usuki K, Sakura T, Kobayashi Y et al. Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: an open-label phase 1 study. Cancer Sci. 109(10), 3235–3244 (2018).
  Medline CASGoogle Scholar
• 21. Perl AE, Altman JK, Cortes J et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study. Lancet Oncol. 18(8), 1061–1075 (2017). • The Phase I–II study examines seven dose-escalation or dose-expansion cohorts (from 20 to 450 mg) of gilteritinib. Maximum tolerated dose was established in 300 mg/day. The results led to the Phase III trial with the once-daily 120 mg as the target dose.
  Medline CASGoogle Scholar
• 22. Perl AE, Martinelli G, Cortes JE et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N. Engl. J. Med. 381(18), 1728–1740 (2019). •• The Phase III study shows an overall survival benefit with gilteritinib monotherapy compared with salvage chemotherapy in relapsed/refractory acute myeloid leukemia.
  Medline CASGoogle Scholar
• 23. Perl AE, Martinelli G, Neubauer A et al. Long-term survivors and gilteritinib safety beyond one year in FLT3-mutated R/R AML: ADMIRAL trial follow-up [abstract]. J. Clin. Oncol. 38(Suppl. 15), 7514–7514 (2020).
  Google Scholar
• 24. Altman JK, Perl AE, Cortes JE et al. Deep molecular response to gilteritinib to improve survival in FLT3 mutation-positive relapsed/refractory acute myeloid leukemia [abstract]. J. Clin. Oncol. 35(Suppl. 15), 7003–7003 (2017).
  Google Scholar
• 25. Levis M, Altman J, Perl A et al. Evaluation of the impact of signal ratio on overall survival in FLT3-mutation-positive relapsed/refractory acute myeloid leukemia following once-daily treatment with gilteritinib [abstract]. Haematologica (102), 216–217 (2017).
  Google Scholar
• 26. Kim RS, Yaghy A, Wilde LR, Shields CL. An iridociliochoroidal myeloid sarcoma associated with relapsed acute myeloid leukemia with FLT3-ITD mutation, treated with gilteritinib, an FLT3 inhibitor. JAMA Ophthalmol. 138(4), 418–419 (2020).
  MedlineGoogle Scholar
• 27. Canaani J, Rea B, Sargent R et al. Differentiation response to gilteritinib (ASP2215) in relapsed/refractory FLT3 mutated acute myeloid leukemia patients is associated with co-mutations in NPM1 and DNMT3A [abstract]. Haematologica 101, 42 (2016).
  Google Scholar
• 28. McMahon CM, Canaani J, Rea B et al. Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia. Blood Adv. 3(10), 1581–1585 (2019).
  Medline CASGoogle Scholar
• 29. Yun HD, Nathan S, Larson M et al. Erythroid differentiation of myeloblast induced by gilteritinib in relapsed FLT3-ITD-positive acute myeloid leukemia. Blood Adv. 3(22), 3709–3712 (2019).
  MedlineGoogle Scholar
• 30. Yong A, Chandran N. Mucocutaneous Sweet syndrome associated with the FLT3-inhibitor gilteritinib. Br. J. Dermatol. 181, 134 (2019).
  Google Scholar
• 31. Levis M, Smith C, Litzow M et al. Drug-drug interaction potential of gilteritinib in healthy subjects and patients with relapsed/refractory acute myeloid leukemia [abstract]. Haematologica 102, 386 (2017).
  Google Scholar
• 32. Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: role of the pharmacist in risk assessment, prevention and management. Canadian Pharmacists Association 149(3), 139–152 (2016).
  MedlineGoogle Scholar
• 33. Lam SSY, Leung AYH. Overcoming resistance to FLT3 inhibitors in the treatment of flt3-mutated aml. Int. J. Mol. Sci. 21(4), 1537 (2020). • Discusses the resistance mechanisms which play a role in FLT3 inhibitor resistance.
  CASGoogle Scholar
• 34. McMahon CM, Canaani J, Rea B et al. Mechanisms of acquired resistance to gilteritinib therapy in relapsed and refractory FLT3-mutated acute myeloid leukemia [abstract]. Blood 130(Suppl. 1), 295–295 (2017).
  Google Scholar
• 35. McMahon CM, Ferng T, Canaani J et al. Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. Cancer Discov. 9(8), 1050–1063 (2019). • Highlights the emergence of treatment-emergent mutations that activate RAS/MAPK pathway after use of gilteritinib leading to resistance.
  Medline CASGoogle Scholar
• 36. Wei AH, Roberts AW. Polyclonal heterogeneity: the new norm for secondary clinical resistance to targeted monotherapy in relapsed leukemia? Cancer Discov. 9(8), 998–1000 (2019).
  Medline CASGoogle Scholar
• 37. Smith CC, Levis MJ, Perl AE et al. Emerging mutations at relapse in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia who received gilteritinib therapy in the Phase III Admiral Trial [abstract]. Blood 134(Suppl. 1), 14–14 (2019).
  Google Scholar
• 38. Hayashi M, Kikushige Y, Harada T, Miyamoto T, Maeda T, Akashi K. Somatic mutations potentiating RAS-MAPK signaling confer resistant potential against FLT3-inhibitors to acute myelogenous leukemia [abstract]. Blood 134(Suppl. 1), 910–910 (2019).
  Google Scholar
• 39. Cella D, Ritchie EK, Fabbiano F et al. The relationship between transplant status and patient-reported outcomes in patients with FLT3-mutated relapsed/refractory (R/R) acute myeloid leukemia (AML): results from the phase III admiral study [abstract]. Blood 134(Suppl. 1), 3850–3850 (2019).
  Google Scholar
• 40. Cella D, Ritchie E, Fabbiano F et al. PCN485 patient-reported outcomes and their relationship with clinical outcomes in patients with FLT3-mutated (FLT3MUT+) relapsed/refractory (R/R) acute myeloid leukemia (AML): results from the Phase III Admiral Study [abstract]. Value Heal. 22, S531–S531 (2019).
  Google Scholar
• 41. Ritchie EK, Cella D, Fabbiano F et al. The relationship between hospitalization and patient-reported outcomes (PROs) in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): results from the phase III admiral study [abstract]. Blood 134(Suppl. 1), 1332–1332 (2019).
  Google Scholar
• 42. Cortes JE, Altman J, Ritchie EK et al. A Phase II/III, multicenter, open-label, 3-arm study of gilteritinib, gilteritinib plus azacitidine, or azacitidine alone in the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia (AML) patients ineligible for intensive induction chemotherapy [abstract]. J. Clin. Oncol. 35(15), TPS7068–TPS7068 (2017).
  Google Scholar
• 43. Pratz K, Cherry M, Altman JK et al. Preliminary results from a Phase I study of gilteritinib in combination with induction and consolidation chemotherapy in subjects with newly diagnosed acute myeloid leukemia (AML) [abstract]. Blood 130(Suppl. 1), 564–564 (2017).
  Google Scholar
• 44. Luger SM, Sun Z, Loghavi S et al. Phase II randomized trial of gilteritinib vs midostaurin in newly diagnosed FLT3 mutated acute myeloid leukemia (AML) [abstract]. Blood 134(Suppl. 1), 1309–1309 (2019).
  Google Scholar
• 45. Levis MJ, Hamadani M, Logan BR et al. BMT CTN protocol 1506: a phase III trial of gilteritinib as maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with FLT3-ITD+ AML [abstract]. Blood 134(Suppl. 1), 4602–4602 (2019).
  Google Scholar
• 46. Perl AE, Daver NG, Pratz KW et al. Venetoclax in combination with gilteritinib in patients with relapsed/refractory acute myeloid leukemia: a Phase 1B study [abstract]. Blood 134(Suppl. 1), 3910–3910 (2019).
  Google Scholar